Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

NCT04838860 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped Internal Company Decision

Conditions

Idiopathic Multicentric Castleman's Disease

Interventions

DRUG: Siltuximab

Sponsor

RECORDATI GROUP